Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A.

Minerva Endocrinol. 2013 Dec;38(4):389-94.

PMID:
24285106
2.

MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.

Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S, Persani L, Beck-Peccoz P, Spada A.

Eur J Endocrinol. 2012 Aug;167(2):157-64. doi: 10.1530/EJE-12-0117. Epub 2012 May 10.

3.

A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.

Falchetti A, Cilotti A, Vaggelli L, Masi L, Amedei A, Cioppi F, Tonelli F, Brandi ML.

Nat Clin Pract Endocrinol Metab. 2008 Jun;4(6):351-7. doi: 10.1038/ncpendmet0816. Epub 2008 Apr 15. Erratum in: Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):420. Vagelli, Luca [corrected to Vaggelli, Luca].

PMID:
18414463
4.

Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.

Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A.

Clin Endocrinol (Oxf). 2008 Nov;69(5):756-62. doi: 10.1111/j.1365-2265.2008.03301.x. Epub 2008 May 14.

PMID:
18485119
5.

Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.

Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, Viccica G, Pinchera A, Marcocci C.

J Endocrinol Invest. 2012 Jul;35(7):655-60. doi: 10.3275/7970. Epub 2011 Sep 30.

PMID:
21971564
6.

Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

Iglesias P, Ais G, González A, Tajada P, García Arévalo C, Fernández Pardo E, Díez JJ.

Am J Med Sci. 2008 Feb;335(2):111-4. doi: 10.1097/MAJ.0b013e3181379f3e.

PMID:
18277118
7.

Update on the use of cinacalcet in the management of primary hyperparathyroidism.

Marcocci C, Cetani F.

J Endocrinol Invest. 2012 Jan;35(1):90-5. doi: 10.3275/8112. Epub 2011 Nov 21. Review.

PMID:
22104762
8.

[Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].

Arranz Martín A, Azcárate Villalón A, Luque Ramírez M, Santana Durán B, Marazuela Azpíroz M, Paniagua Ruiz A, Carraro R, Gómez Pan A.

Endocrinol Nutr. 2011 Jan;58(1):24-31. doi: 10.1016/j.endonu.2010.09.009. Spanish.

PMID:
21277266
9.

Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Duntas LH, Stathatos N.

Endocrine. 2011 Jun;39(3):199-204. doi: 10.1007/s12020-011-9452-7. Epub 2011 Mar 26. Review.

PMID:
21442382
10.

Cinacalcet for the treatment of primary hyperparathyroidism.

Dillon ML, Frazee LA.

Am J Ther. 2011 Jul;18(4):313-22. doi: 10.1097/MJT.0b013e3181bdc3d0. Review.

PMID:
20228675
11.

Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.

Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A, Panico F, Savastano S, Lombardi G, Colao A, Gasperi M.

Endocrine. 2011 Jun;39(3):283-7. doi: 10.1007/s12020-011-9459-0. Epub 2011 Mar 29.

PMID:
21445714
12.

Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.

Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M.

Calcif Tissue Int. 2011 Jul;89(1):29-35. doi: 10.1007/s00223-011-9490-4. Epub 2011 May 4.

PMID:
21541686
13.

Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.

J Clin Endocrinol Metab. 2011 Jan;96(1):E9-18. doi: 10.1210/jc.2010-1221. Epub 2010 Oct 13.

14.

Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation.

Pinho LR, Ribeiro Santos MJ, Pestana Vasconcelos M.

Clin Nephrol. 2011 Mar;75(3):263-8.

PMID:
21329638
15.

Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy.

Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E.

World J Surg. 2013 Aug;37(8):1966-72. doi: 10.1007/s00268-013-2054-1.

PMID:
23722465
16.

Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.

Paschoalin RP, Torregrosa JV, Sánchez-Escuredo A, Barros X, Durán CE, Campistol JM.

Transplant Proc. 2012 Nov;44(9):2588-9. doi: 10.1016/j.transproceed.2012.09.049.

PMID:
23146463
17.

Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype.

Pieterman CR, van Hulsteijn LT, den Heijer M, van der Luijt RB, Bonenkamp JJ, Hermus AR, Borel Rinkes IH, Vriens MR, Valk GD; DutchMEN1 Study Group.

Ann Surg. 2012 Jun;255(6):1171-8. doi: 10.1097/SLA.0b013e31824c5145.

PMID:
22470073
18.

Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.

Dong BJ.

Clin Ther. 2005 Nov;27(11):1725-51. Review.

PMID:
16368445
19.

[Medical treatment of primary hyperparathyroidism: role of calcimimetics].

Muñoz Torres M, García Martín A.

Endocrinol Nutr. 2009 Apr;56 Suppl 1:29-34. doi: 10.1016/S1575-0922(09)70853-8. Epub 2009 May 18. Spanish.

PMID:
19627758
20.

Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.

Norman J, Lopez J, Politz D.

Ann Surg Oncol. 2012 May;19(5):1466-71. doi: 10.1245/s10434-011-2065-9. Epub 2011 Sep 16.

PMID:
21922336
Items per page

Supplemental Content

Write to the Help Desk